Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Development of medications for the treatment of opiate and cocaine addictions [[electronic resource] ] : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine
| Development of medications for the treatment of opiate and cocaine addictions [[electronic resource] ] : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine |
| Pubbl/distr/stampa | Washington, DC, : National Academy Press, 1995 |
| Descrizione fisica | xvii, 250 p. : ill |
| Disciplina | 616.86/32061 |
| Altri autori (Persone) |
FulcoCarolyn
LivermanCatharyn T EarleyLaurence E |
| Soggetto topico |
Drug addiction - Treatment
Cocaine abuse - Treatment Substance abuse - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-19299-2
9786610192991 0-309-58791-3 0-585-02541-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910456005403321 |
| Washington, DC, : National Academy Press, 1995 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Development of medications for the treatment of opiate and cocaine addictions [[electronic resource] ] : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine
| Development of medications for the treatment of opiate and cocaine addictions [[electronic resource] ] : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine |
| Pubbl/distr/stampa | Washington, DC, : National Academy Press, 1995 |
| Descrizione fisica | xvii, 250 p. : ill |
| Disciplina | 616.86/32061 |
| Altri autori (Persone) |
FulcoCarolyn
LivermanCatharyn T EarleyLaurence E |
| Soggetto topico |
Drug addiction - Treatment
Cocaine abuse - Treatment Substance abuse - Treatment |
| ISBN |
0-309-17652-2
1-280-19299-2 9786610192991 0-309-58791-3 0-585-02541-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910778654103321 |
| Washington, DC, : National Academy Press, 1995 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine
| Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Washington, DC, : National Academy Press, 1995 |
| Descrizione fisica | xvii, 250 p. : ill |
| Disciplina | 616.86/32061 |
| Altri autori (Persone) |
FulcoCarolyn
LivermanCatharyn T EarleyLaurence E |
| Soggetto topico |
Drug addiction - Treatment
Cocaine abuse - Treatment Substance abuse - Treatment |
| ISBN |
0-309-17652-2
1-280-19299-2 9786610192991 0-309-58791-3 0-585-02541-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector -- Copyright -- Acknowledgments -- Preface -- Note to the Reader -- Contents -- Executive Summary -- STATE OF THE SCIENTIFIC KNOWLEDGE ON ADDICTION -- NIDA'S MEDICATIONS DEVELOPMENT DIVISION -- EFFECTIVENESS OF TREATMENT -- TREATMENT FINANCING -- TRAINING AND EDUCATION -- FEDERAL REGULATORY ISSUES -- Food and Drug Administration -- Drug Enforcement Administration -- STATE REGULATORY ISSUES -- Interim Actions -- Long-Term Actions -- MARKET OBSTACLES AND CREATING INCENTIVES -- Size of the Market -- Drug Pricing and Intellectual Property Rights -- Societal Stigma -- NEED FOR FEDERAL LEADERSHIP -- CONCLUSIONS -- OPTIONS FOR FURTHER CONSIDERATION -- REFERENCES -- 1 Introduction -- PUBLIC-HEALTH REPERCUSSIONS OF ILLICIT DRUG USE -- Health Consequences: Violence -- Health Consequences: AIDS -- Health Consequences: Tuberculosis -- Health Consequences: Drug-exposed Infants -- ECONOMIC COSTS OF ILLICIT DRUG USE TO SOCIETY -- EXTENT OF ILLICIT DRUG USE -- ROLE OF PHARMACOTHERAPY -- REFERENCES -- 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction -- CONCEPTS OF DRUG ADDICTION -- BIOLOGICAL CORRELATES AND PSYCHOPHARMACOLOGY OF ADDICTION -- Opiate Addiction -- Cocaine Addiction -- MDD AND STRATEGIES FOR THE DISCOVERY OF A COCAINE MEDICATION: DESCRIPTION AND CRITICAL ANALYSIS -- Introduction -- Source of Compounds -- Medication Preclinical Screening -- In Vitro Screen-Receptors and Mechanisms of Action -- In Vivo Screen-Behavioral Tests -- Specific Conclusions and Recommendations for the MDD -- Clinical Trials -- Human Behavioral Models -- CONCLUSIONS AND RECOMMENDATIONS -- REFERENCES -- 3 Assessment of the Medications Development Division -- STRUCTURE AND FUNCTIONS OF THE MEDICATIONS DEVELOPMENT DIVISION.
Mission and History -- Research Focus on Opiates and Cocaine -- Program Objectives -- Organizational Structure -- Budget Process -- Resources and Funding Instruments -- Types of Grants and Contracts -- Interagency Agreements -- CRADAs -- Screening Agreements -- Training -- RELATIONSHIPS WITH OTHER FEDERAL AGENCIES AND THE PRIVATE SECTOR -- Food and Drug Administration -- Drug Enforcement Administration -- Office of Protection from Research Risks -- Pharmaceutical Industry -- ASSESSMENT OF THE MEDICATIONS DEVELOPMENT DIVISION -- Staff and Resources -- Drug-Discovery Programs -- Clinical Trials -- Clinical-Research Training -- Relationships with Regulatory Agencies -- Interaction with the Private Sector -- SUMMARY -- CONCLUSIONS AND RECOMMENDATIONS -- REFERENCES -- 4 Treatment Setting and Effectiveness -- TREATMENT SETTING -- Opiate Addiction -- Cocaine Addiction -- DEMOGRAPHIC AND FINANCIAL PROFILE -- Opiate-Dependent Patients -- Cocaine-Dependent Patients -- TREATMENT EFFECTIVENESS AND COST-EFFECTIVENESS -- Methadone Maintenance Treatment -- Effectiveness -- Cost-Effectiveness -- Cocaine Addiction Treatment -- Effectiveness -- Cost-Effectiveness -- CONCLUSIONS AND RECOMMENDATION -- REFERENCES -- 5 Treatment Financing and Trends in Health Insurance -- FINANCING OF TREATMENT -- Financing the Treatment of Opiate Addiction -- Financing the Treatment of Cocaine Addiction -- FINANCING OF LAAM FOR THE TREATMENT OF OPIATE ADDICTION -- IMPACT OF HEALTH INSURANCE TRENDS ON MEDICATIONS DEVELOPMENT -- Trends in Drug Abuse Treatment Benefits -- REFERENCES -- 6 Training and Education -- EXPANDING THE CORE OF RESEARCHERS AND CLINICIANS -- Training Programs -- Fellowships -- Certification -- Conclusions and Recommendations -- INCREASING KNOWLEDGE AND SKILLS AMONG PRIMARY CARE PHYSICIANS -- Required Education in Medical Schools -- Residency Training. Continuing Education -- Conclusions and Recommendations -- COMPREHENSIVE DRUG ABUSE CENTERS -- Proposed Model -- Existing Research and Training Centers -- CSAT Centers -- NIDA Research Centers -- Conclusions and Recommendations -- SUMMARY -- REFERENCES -- 7 Federal Laws and Regulations -- CREATION OF A DRUG BY THE PHARMACEUTICAL INDUSTRY -- FOOD AND DRUG ADMINISTRATION -- Recent Initiatives to Expedite Availability of New Drugs -- Market Exclusivity and Orphan Drug Status -- FDA Guidelines on Evaluation of Anti-Addiction Drugs -- DRUG ENFORCEMENT ADMINISTRATION -- Scheduling -- Quotas -- Regulatory Authority Over Anti-Addiction Drugs In Development -- CONCLUSIONS -- REFERENCES -- 8 State Laws and Regulations -- STATE REGULATORY LANDSCAPE -- Scheduling -- Treatment -- Admission Criteria -- Staffing Requirements -- Patient Registries -- Drug Screening -- Medication Take-Home Policies -- Clinical Research -- LAAM: A CASE STUDY -- Federal Regulations -- State Regulations -- Scheduling/Rescheduling -- Treatment Regulations -- Clinic Approval -- CONCLUSIONS -- RECOMMENDATIONS -- Interim Actions -- Long-Term Actions -- REFERENCES -- 9 Market Obstacles and Creating Incentives -- MARKET OBSTACLES TO PRIVATE-SECTOR INVESTMENT -- Nature and Size of the Market -- Drug Pricing and Intellectual Property Rights -- Societal Stigma -- Clinical Research on Anti-Addiction Medications -- Product Liability -- NEED FOR FEDERAL LEADERSHIP -- CONCLUSIONS -- OPTIONS FOR FURTHER CONSIDERATION -- REFERENCES -- Appendix A Acknowledgements -- Appendix B Organization and Mission Statements of NIDA's Medications Development Division and Its... -- MEDICATIONS DEVELOPMENT DIVISION MISSION STATEMENT -- Biometrics Branch Mission Statement -- Chemistry and Pharmaceutics Branch Mission Statement -- Clinical Trials Branch Mission Statement. Pharmacology and Toxicology Branch Mission Statement -- Regulatory Affairs Branch Mission Statement -- Appendix C Diagnostic Criteria for Psychoactive Substance Dependence -- Appendix D Survey of Pharmaceutical Companies -- ATTACHMENT 1 -- ATTACHMENT 2 -- Appendix E Model Federal Programs in Pharmaceutical R& -- D -- ANTIEPILEPTIC DRUG DEVELOPMENT PROGRAM -- Background -- Elements of Success -- NATIONAL CANCER INSTITUTE CANCER-DRUG DISCOVERY AND DEVELOPMENT PROGRAMS -- Background -- Preclinical Research -- Clinical Research -- Elements of Success -- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES DRUG DISCOVERY AND DEVELOPMENT PROGRAMS -- Background -- Preclinical Research -- Clinical Research -- Elements of Success -- REFERENCES -- Appendix F Workshop Agenda and Participants -- WORKSHOP AGENDA -- PARTICIPANT LIST -- Appendix G Health Care Reform Legislation -- UNIVERSALITY OF COVERAGE -- PRESCRIPTION DRUG BENEFITS -- DRUG ABUSE TREATMENT BENEFITS -- INSURANCE REFORM -- FINANCING HEALTH CARE REFORM AND THE FATE OF MEDICAID -- CONCLUSIONS -- REFERENCES -- Appendix H Acronyms. |
| Record Nr. | UNINA-9910828852203321 |
| Washington, DC, : National Academy Press, 1995 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of methadone prescribing and buprenorphine therapy / / Ricardo A. Cruciani, Helena Knotkova, editors
| Handbook of methadone prescribing and buprenorphine therapy / / Ricardo A. Cruciani, Helena Knotkova, editors |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | New York, : Springer, c2013 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina | 616.86/32061 |
| Altri autori (Persone) |
CrucianiRicardo A
KnotkovaHelena |
| Soggetto topico |
Methadone maintenance
Buprenorphine |
| ISBN | 1-4614-6974-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Foreword; Preface; Contents; Contributors; Chapter 1: Prescribing Methadone Safely; Introduction; Importance of Methadone Pharmacokinetic in Safe Prescribing; Methadone Safety and the QTc Interval Duration; Understanding Racemic Methadone and Methadone Enantiomers; Reports of Increased Deaths and ED Visits Attributed to Methadone; Methadone Induced QTc Prolongation and TdP; "Windows" for Risk of Toxicity; Opioid Rotation; Resuming Methadone Prescribing After Imprisonment; Missing Doses at the Methadone Clinic; Exit Strategy as an Intervention for Safe Prescribing
General Recommendations for Successful Methadone Prescribing Conclusions; References; Chapter 2: Use of Methadone in Opioid Maintenance Treatment; Introduction; Federal Criteria for Admission to MMT in an OTP; Admission History and Physical Exam; Determining the Methadone Dose; Tolerance; Optimal Dosing; Split Dosing; Possible Side Effects of MMT; Drug Interactions with Methadone; Prolonged QTc and ECG Screening in MMT; Ongoing Care; Comorbid Polysubstance Use; Comorbid Psychopathology; Associated Medical Problems; Chronic and Acute Pain in MMT; Toxicology Screening Take-Home Privileges Pregnancy; Detoxification and Discharge from MMT; References; Chapter 3: Treating Pain in Patients Receiving Methadone Maintenance for Opioid Dependence; Misconceptions About Pain in Patients Receiving Methadone for Opioid Dependence; Treating Acute Pain in Patients Receiving Methadone; Treatment of Chronic Pain in Patients Receiving Methadone; Conclusion; References; Chapter 4: Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System; Introduction; Constipation; Respiratory Depression; Sedation Sleep-Disordered Breathing Endocrine Effects; Concluding Remarks; References; Chapter 5: Cardiovascular Effects of Methadone; Introduction; Mechanism of Action; Cardiovascular Effects: Epidemiological Observations; Cellular Basis: Methadone and the Prolongation of the Myocardial Cell Action Potential; Clinical Example: Long QT Syndrome and Methadone; Conclusion; References; Chapter 6: Methadone Pharmacodynamics and Pharmacokinetics; Background; Acute Pharmacodynamic Actions; Pharmacodynamic Effects: Chronic Administration; Pharmacodynamics in Treatment of Pain Pharmacodynamics in Opioid Maintenance Treatment General Pharmacokinetic Properties; Metabolism and Excretion; Special Patient Populations; Conclusion: Relationship Between Methadone Pharmacodynamics and Pharmacokinetics; References; Chapter 7: Methadone and Opioid Rotation; Opioid Rotation: Definition and Principle; Methadone Characteristics Relevant for Opioid Rotation; Clinical Considerations and Guidelines for Opioid Rotation Involving Methadone; Conclusions; References; Chapter 8: Intravenous Use of Methadone: Efficacy and Safety; Pharmacokinetic Issues of the Intravenous Route Clinical Use |
| Record Nr. | UNINA-9910438009103321 |
| New York, : Springer, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Methadone
| Methadone |
| Autore | Simpson Carolyn |
| Pubbl/distr/stampa | [Place of publication not identified], : Rosen Publ, 1997 |
| Descrizione fisica | 1 online resource (2 unnumbered pages) : color illustrations |
| Disciplina | 616.86/32061 |
| Collana | The drug abuse prevention library Methadone |
| Soggetto topico |
Methadone maintenance - Treatment
Heroin abuse |
| ISBN | 0-585-07322-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910703085603321 |
Simpson Carolyn
|
||
| [Place of publication not identified], : Rosen Publ, 1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||